Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections
See attached press release
Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate
See attached press release
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials
See attached press release
Centauri Therapeutics appoints Dr. Debra Barker as Chief Medical Officer
See attached press release
Centauri Therapeutics publishes proof-of-concept data demonstrating activity of a novel bifunctional immunotherapy against Gram-negative bacterial infections
See attached press release
Centauri Therapeutics selects first clinical candidate, for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the…
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Centauri is excited to announce that we have been selected to receive a £1M grant under the first round of @PACE-AMR funding which will support…
Centauri Therapeutics closes £24m Series A investment round
Centauri Therapeutics is delighted to announce new investment of £24m in antimicrobial research and appointment of new company directors. See attached press release
Centauri awarded follow-on CARB-X grant
Centauri Therapeutics Limited, an immunotherapy company focused on the treatment of infectious diseases, has been awarded a grant of up to $2.7 million USD (c.£2…